Pulmonary Hypertension Specific Intravenous Therapy

Dunbar Ivy, MD presented this overview of the intravenous therapies specific to pulmonary hypertension at the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference. Dr. Ivy covers intravenous Epoprostenol, subcutaneous and intravenous Treprostinil as well as combination therapy.

Course Author

Dunbar Ivy, MD

Professor of Pediatrics
Chief and Selby's Chair of Pediatric Cardiology
University of Colorado
Denver, CO

Course Chairs:

Ian Adatia, MBChB

Professor of Pediatrics
University of Alberta
Director, Pediatric Cardiac Critical and Intermediate Care Program
Director, Pediatric Pulmonary Hypertension Clinic
Stollery Children's Hospital
Edmonton, Canada

Jeffrey Fineman, MD

Professor of Pediatrics
Investigator, Cardiovascular Research Institute
UCSF Children's Hospital
San Francisco, California

Educational Objectives for the Neonatal and Childhood Pulmonary Vascular Disease Conference

An attendee of this conference should be able to incorporate the following elements into clinical practice for improved patient care outcomes:

1. The developmental vascular biology of neonatal pulmonary vascular disease;
2. The pharmacology and clinical use ofestablished and emerging therapies for neonatal and childhood pulmonary vascular disease;
3. The current and novel mechanical support treatment strategies for childhood pulmonary vascular disease;
4. The use of anesthesia in children with pulmonary hypertension;
5. Understanding the value of pulmonary hypertension networks for children and neonates.

Accreditation and Credit Designation

The University of California, San Francisco School of Medicine (UCSF) isaccredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Instructions for Earning Credit

This activity is a self-study program. Upon entering the activity, participants should read the text, examine any images and/or multimedia features, and review the content presented within all of the links provided. Once the course has been reviewed in its entirety, participants will be asked to complete a post-test and evaluation online. Participants must receive a test score of 100% in order to proceed to the course evaluation; the post-test can be repeated until all questions are answered correctly. All evaluation questions must be completed in order to receive a certificate of credit. If needed, participants may save their answers and complete the course at a later date. Saved courses can be found on the "My Activities" page, accessed via "My Account" at the top of the page.

Faculty Disclosures

Disclosure of faculty and commercial relationships is listed below.

Dunbar Ivy, MD, indicates that he has Consultant for Actelion, Pfizer and United Therapeutics and is on the grant review panel for Gilead.
Ian Adatia, MBChB, indicates that he has no financial relationships to disclose.
Jeffrey Fineman, MD, indicates that he has no financial relationships to disclose.

Disclaimer

The information presented in this activity reflects the views of the faculty only and not necessarily those of the Pulmonary Hypertension Association (PHA) or University of California San Francisco. All participants should verify the information and data presented before treating patients or utilizing any therapies noted in these materials. No portion of this activity may be reproduced without the expressed written consent of PHA.

Privacy Policy

For information about the PHA's privacy policy, visit http://www.PHAssociation.org/PrivacyPolicy .

The recording of these sessions was made possible by a grant from the Cardiovascular Medical Research Fund.

©2011 Pulmonary Hypertension Association, 801 Roeder Road, Suite 1000, Silver Spring, MD 20910.